Published in J Clin Invest on April 12, 2010
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
From vaccines to memory and back. Immunity (2010) 3.30
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature (2013) 2.08
Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol (2012) 2.07
A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis (2014) 2.04
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One (2011) 2.02
Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature (2012) 1.93
Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med (2010) 1.90
A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol (2011) 1.85
Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. Proc Natl Acad Sci U S A (2011) 1.74
Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol (2013) 1.69
Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol (2011) 1.68
The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog (2013) 1.67
The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol (2013) 1.66
Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature (2014) 1.65
Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS One (2011) 1.55
Distinct germinal center selection at local sites shapes memory B cell response to viral escape. J Exp Med (2015) 1.50
Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol (2012) 1.50
Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med (2013) 1.49
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A (2014) 1.49
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol (2013) 1.49
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis (2013) 1.47
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nat Immunol (2014) 1.43
Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A (2010) 1.42
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis (2012) 1.41
Structural basis of influenza virus neutralization. Ann N Y Acad Sci (2011) 1.37
Influenza vaccine responses in older adults. Ageing Res Rev (2010) 1.35
A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A (2013) 1.34
Tools to therapeutically harness the human antibody response. Nat Rev Immunol (2012) 1.30
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest (2015) 1.27
Targeting B cell responses in universal influenza vaccine design. Trends Immunol (2011) 1.27
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol (2014) 1.26
Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A (2012) 1.22
Traditional and new influenza vaccines. Clin Microbiol Rev (2013) 1.22
The wages of original antigenic sin. Emerg Infect Dis (2010) 1.21
Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol (2011) 1.21
Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol (2012) 1.20
Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol (2014) 1.15
A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol (2012) 1.15
Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. Cell (2016) 1.14
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol (2013) 1.13
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol (2011) 1.13
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest (2016) 1.12
Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog (2014) 1.11
Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med (2015) 1.09
Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination. PLoS One (2013) 1.07
Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med (2015) 1.06
New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion. J Virol (2013) 1.04
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses (2014) 1.04
Advances in structure-based vaccine design. Curr Opin Virol (2013) 1.04
Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis (2011) 1.03
Universal immunity to influenza must outwit immune evasion. Front Microbiol (2014) 1.03
The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses. J Mol Genet Med (2013) 1.03
Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. J Virol (2011) 1.03
Viva la revolución: rethinking influenza a virus antigenic drift. Curr Opin Virol (2011) 1.02
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel) (2014) 1.01
N-linked glycosylation in the hemagglutinin of influenza A viruses. Yonsei Med J (2012) 1.01
Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS Pathog (2011) 1.01
Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion. J Virol (2011) 1.00
Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol (2013) 0.99
A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol (2012) 0.99
To dream the impossible dream: universal influenza vaccination. Curr Opin Virol (2013) 0.98
Re-engaging cross-reactive memory B cells: the influenza puzzle. Front Immunol (2012) 0.97
High-resolution temporal response patterns to influenza vaccine reveal a distinct human plasma cell gene signature. Sci Rep (2013) 0.97
A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One (2011) 0.97
The prospects and challenges of universal vaccines for influenza. Trends Microbiol (2013) 0.97
The diversity of the immune response to the A2 domain of human factor VIII. Blood (2013) 0.96
Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malar J (2010) 0.96
Restricted, canonical, stereotyped and convergent immunoglobulin responses. Philos Trans R Soc Lond B Biol Sci (2015) 0.95
Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast. J Biol Chem (2011) 0.93
A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus. J Virol (2012) 0.92
A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS One (2012) 0.91
Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J Immunol Res (2014) 0.91
Epidemiology of the influenza A virus H5N1 subtype and memory of immunity to the H2N2 subtype. MBio (2012) 0.90
Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus. PLoS One (2011) 0.90
Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice. Vaccine (2011) 0.90
Screening of random peptide library of hemagglutinin from pandemic 2009 A(H1N1) influenza virus reveals unexpected antigenically important regions. PLoS One (2011) 0.89
Universal influenza vaccines, a dream to be realized soon. Viruses (2014) 0.89
Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J Immunol (2015) 0.89
Focused antibody response to influenza linked to antigenic drift. J Clin Invest (2015) 0.89
Pseudotype-based neutralization assays for influenza: a systematic analysis. Front Immunol (2015) 0.88
Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One (2012) 0.88
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med (2016) 0.87
Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci U S A (2014) 0.87
Strategies to guide the antibody affinity maturation process. Curr Opin Virol (2015) 0.87
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine (2011) 0.87
Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J Infect Dis (2012) 0.86
Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J Virol (2012) 0.86
Evolution and ecology of influenza A viruses. Microbiol Rev (1992) 39.99
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 19.03
Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature (1981) 15.85
Mapping the antigenic and genetic evolution of influenza virus. Science (2004) 14.28
The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell (1982) 12.44
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol (2005) 10.77
Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med (1966) 9.26
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One (2008) 6.98
A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol (1993) 6.26
Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol (1990) 5.37
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A (2008) 4.67
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med (2006) 3.71
H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology (2004) 2.67
Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med (2009) 2.47
The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos Trans R Soc Lond B Biol Sci (2001) 2.29
Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog (2009) 2.29
Variation and infectivity neutralization in influenza. Immunology (2006) 2.23
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis (2008) 1.98
A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses (2007) 1.92
Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol (2009) 1.74
Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol (1994) 1.72
Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. J Virol (1986) 1.65
Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol (2002) 1.52
Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine. Nat Med (2009) 1.49
Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology (2006) 1.45
Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest (1996) 1.35
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine (2009) 1.19
Antigenic determinants of influenza virus hemagglutinin. III. Competitive binding of antibodies directed against "common" and "strain-specific" antigenic determinants of A/Memphis/72 hemagglutinin. J Immunol (1979) 1.01
Pandemic vaccine preparedness--have we left something behind? PLoS Pathog (2009) 0.90
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol (2007) 13.70
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 7.86
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (2004) 7.07
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol (2009) 5.97
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol (2009) 4.69
Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe (2008) 4.55
Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol (2002) 4.17
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol (2006) 3.85
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature (2012) 3.85
A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood (2003) 3.77
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med (2006) 3.71
T cell fitness determined by signal strength. Nat Immunol (2003) 3.65
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63
Clonal origin and evolution of a transmissible cancer. Cell (2006) 3.60
The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
From vaccines to memory and back. Immunity (2010) 3.30
Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med (2005) 3.29
Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 3.23
Understanding the generation and function of memory T cell subsets. Curr Opin Immunol (2005) 3.22
Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol (2002) 3.07
Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev (2008) 3.07
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
T cell costimulation by chemokine receptors. Nat Immunol (2005) 3.00
Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol (2006) 2.94
Broadly neutralizing antiviral antibodies. Annu Rev Immunol (2013) 2.77
A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog (2007) 2.71
CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol (2011) 2.54
L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol (2007) 2.51
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis (2013) 2.51
Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med (2009) 2.47
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med (2004) 2.38
Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins. J Virol (2004) 2.38
Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol (2010) 2.34
Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol (2009) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
IL-36R ligands are potent regulators of dendritic and T cells. Blood (2011) 2.20
Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity (2013) 2.13
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood (2012) 2.00
Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol (2009) 1.92
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92